IDNA - Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval

• Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories.
• About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if Omicron variant doesn't resurge, then it's possible sales could improve further.
• Two presentations of results of AURORA-2 study using Lupkynis for LN expected end of May and in June of 2022; from there, manuscript of full results expected 2nd half of 2022.
• The global lupus nephritis market could reach $3.1 billion by 2027.

For further details see: